News Snapshot:
| Health BEIJING, Aug.16 (Xinhua) – An inactivated vaccine candidate against COVID-19 developed by China is safe and generates an immune response, according to clinical trial data published in the Journal of the American Medical Association this week. The research article provided a provisional analysis of the Phase 1 and Phase 2 clinical trials of an inactivated COVID-19 vaccine developed by the Wuhan Institute of Biologics under the China National Biotec Group (CNBG ), affiliated with Sinopharm, and the Wuhan Institute of Virology under the Chinese Academy of Sciences. This research involves 320 healthy volunteers between the ages of 18...
